RxDoctor Payments Data

Pamela Britnell

Family · Sheffield, ALNPI 1952356057

Payments from drug & device makers

$2,309in general payments, 2019–2025

Across 98 payments — averaging $23.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$988
  • AstraZeneca$315
  • AbbVie$240
  • Lilly USA, LLC$218
  • Phathom Pharmaceuticals, Inc.$203
  • Pfizer$86
  • plus $259 from 11 others

What the payments were for

  • Food & beverage$2,309100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,309 in reported general payments places this provider in the 75th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$175,121
Medicare patients
461
Services billed
5,724

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$69,611
RybelsusSemaglutide35$55,253
EliquisApixaban57$45,917
JanuviaSitagliptin Phosphate16$11,234
JardianceEmpagliflozin11$9,799
SymbicortBudesonide/Formoterol Fumarate14$4,096
Levothyroxine Sodium198$2,514
Venlafaxine Hcl ErVenlafaxine Hcl18$2,191
Esomeprazole Magnesium33$2,002
CefuroximeCefuroxime Axetil123$1,812
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen84$1,810
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$1,626
Omeprazole130$1,605
Bupropion XlBupropion Hcl45$1,550
Valsartan53$1,501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$988$124,86491 claims
PfizerEliquis$86$45,91757 claims
AstraZenecaSymbicort$315$4,09614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,415 family providers in Alabama.

Other family in Sheffield

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →